Cogent Biosciences announced preclinical results for CGT1145, a novel JAK2 V617F mutant-selective inhibitor, at the 2026 European Hematology Association Congress. CGT1145 shows high selectivity and potency against the JAK2 V617F mutation, which is common in certain blood cancers like polycythemia vera and myelofibrosis. The drug candidate aims to target the disease's root cause while reducing side effects seen with current treatments. Cogent plans to submit an Investigational New Drug application for CGT1145 in 2026, advancing its development toward clinical trials.
China's 15th Five-Year Plan (2026-2030) focuses on innovation, resilience, and quality growth, aiming to lead in sectors like quantum computing and 5G. Former EU economist Rudy Aernoudt highlights China's clear, unified long-term planning approach as...
Hypersurface has acquired Acre to create the Hypersurface Bitcoin Premium Income vault (HSBPI), the first fully on-chain Bitcoin volatility trading strategy. This new product allows Bitcoin holders to deposit BTC directly and earn premium income thro...
Muskrat Dam First Nation in northern Ontario was connected to the provincial power grid on April 9, 2026, allowing the community to shut down costly diesel generators. This connection removes previous power constraints, enabling new construction proj...
Zealthy has introduced an upgraded virtual weight-loss care platform that integrates telehealth services, insurance coordination, prescription management, and patient support. The platform allows eligible patients to complete an online health assessm...
EARNED, a baseball culture brand, has signed Cody Boshell, a leading 2026 MLB Draft prospect and University of Tennessee commit, as a brand ambassador. Boshell is recognized for his powerful left-handed batting and strong work ethic, aligning with EA...
